Margaretha G.M. Roemer

<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Margaretha G.M. Roemer, Ranjana H. Advani, Azra H. Ligon et al. · Journal of Clinical Oncology · 2016 · 783 citations · Full text

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

Margaretha G.M. Roemer, Ranjana H. Advani, Robert Redd et al. · Cancer Immunology Research · 2016 · 183 citations · Full text

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

Jossie Rotman, Leontine A. S. den Otter, Maaike C.G. Bleeker et al. · Frontiers in Immunology · 2020 · 101 citations · Full text

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra et al. · Blood Cancer Journal · 2021 · 94 citations · Full text

Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics

Paul Roepman, Ewart de Bruijn, Stef van Lieshout et al. · Journal of Molecular Diagnostics · 2021 · 76 citations · Full text